Edition:
United States

Vita 34 AG (V3VGn.DE)

V3VGn.DE on Xetra

9.08EUR
18 Aug 2017
Change (% chg)

€-0.24 (-2.61%)
Prev Close
€9.32
Open
€8.99
Day's High
€9.16
Day's Low
€8.96
Volume
37,211
Avg. Vol
14,338
52-wk High
€9.51
52-wk Low
€3.79

V3VGn.DE

Chart for V3VGn.DE

About

Vita 34 AG, is a Germany-based company that operates as an umbilical cord blood bank. It operates through the Stem Cell Storage and the Biotechnology segment. The Stem Cell Storage segment collects, processes, and stores stem cells from umbilical cord blood and umbilical cord tissue, as well as develops cell therapy procedures.... (more)

Overall

Beta: 0.06
Market Cap(Mil.): €37.65
Shares Outstanding(Mil.): 4.15
Dividend: 0.16
Yield (%): 1.71

Financials

  V3VGn.DE Industry Sector
P/E (TTM): 40.92 29.35 32.56
EPS (TTM): 0.22 -- --
ROI: 2.33 6.60 14.89
ROE: 2.84 10.47 16.13

BRIEF-Vita 34 adjusts revenues and earnings targets for 2017

* DGAP-ADHOC: VITA 34 ADJUSTS REVENUES AND EARNINGS TARGETS FOR 2017

Aug 08 2017

BRIEF-VITA 34 resolves on cash capital increase

* SAID ON MONDAY VITA 34 AG RESOLVES TO IMPLEMENT RIGHTS ISSUE AGAINST CASH CONTRIBUTIONS BY USING ITS AUTHORIZED CAPITAL

Jul 11 2017

BRIEF-Vita 34 elects new supervisory board members

* REPORTED ON WEDNESDAY ON ANNUAL GENERAL MEETING AND DIVIDEND DISTRIBUTION

Jun 29 2017

BRIEF-Vita 34 to cooperate with Romanian Besmax Life Solutions SRL

* DGAP-NEWS: VITA 34 AG SIGNS COOPERATION AGREEMENT WITH ROMANIAN COMPANY BESMAX LIFE SOLUTIONS SRL

Jun 27 2017

BRIEF-Vita 34 ag wins MK Beleggingsmaatschappij Venlo B.V. as new strategic investor

* SAID ON WEDNESDAY ACQUIRES MK BELEGGINGSMAATSCHAPPIJ VENLO B.V. AS A NEW STRATEGIC INVESTOR AND SECURES SUPPORT FOR FURTHER CORPORATE ACTION

Jun 15 2017

BRIEF-Vita 34 decides on a capital increase of around 10 pct

* DGAP-ADHOC: VITA 34 AG DECIDES ON A CAPITAL INCREASE OF AROUND 10%

Jun 14 2017

BRIEF-Vita 34 updates on planned capital increase and changes in management

* DGAP-ADHOC: VITA 34 AG UPDATES ON PLANNED CAPITAL INCREASE AND CHANGES IN THE MANAGEMENT

Jun 12 2017

BRIEF-Vita 34 Q1 EBITDA nearly doubling to EUR 0.7 million

* Q1 REVENUES INCREASED IN FIRST THREE MONTHS BY 7.1 PERCENT TO EUR 4.1 MILLION

May 16 2017

BRIEF-Vita 34 AG CFO Falk Neukirch has resigned

* Vita 34 AG: chief financial officer of Vita 34 AG to seek new challenges

May 01 2017

BRIEF-Vita 34 says to buy competitor Seracell Pharma

* dgap-adhoc: vita 34 ag: vita 34 concludes purchase agreement for the entire acquisition of its competitor seracell pharma ag

Apr 20 2017

Earnings vs. Estimates